Michael L. Corrado* INC Research, 580 Union Square Drive, New Hope, PA 18938, USA
|
|
- Arthur Wiggins
- 5 years ago
- Views:
Transcription
1 J Antimicrob Chemother 2010; 65 Suppl 4: iv67 71 doi: /jac/dkq256 Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections Michael L. Corrado* INC Research, 580 Union Square Drive, New Hope, PA 18938, USA *Tel: , ext. 6212; Fax: ; mlcorrado4444@yahoo.com Objectives: Treatment of complicated skin and skin structure infections (csssis) requires therapy that is effective against a range of Gram-positive and Gram-negative bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus. Equally important is the need to provide therapy that is safe and well tolerated. fosamil is a new-generation, parenteral cephalosporin that was developed for the treatment of moderate to severe bacterial infections, including csssis. This report provides an integrated safety summary of the CeftAroliNe Versus VAncomycin in Skin and Skin Structure Infections (CANVAS) 1 and 2 studies (registration numbers NCT and NCT ). Methods: Adult patients with csssis requiring intravenous therapy received 600 mg of ceftaroline fosamil every 12 h or 1 g of vancomycin plus 1 g of aztreonam every 12 h for 5 14 days (randomized 1:1). All patients were followed for treatment-emergent adverse events (TEAEs) occurring from the start of the initial study drug infusion up to the test-of-cure visit, 1 week following the last dose of study medication; serious adverse events (SAEs) that occurred within 30 days after the last dose were recorded. Results: A total of 1378 patients received any amount of study drug and were included in the safety analysis. The percentage of patients with an SAE was similar between the ceftaroline fosamil and the vancomycin plus aztreonam groups (4.3% versus 4.1%). The majority of patients (.75%) had either no or mild TEAEs and the distribution of TEAEs based on severity was comparable between the groups. The most commonly reported TEAEs in patients treated with ceftaroline fosamil included nausea (5.9%), headache (5.2%), diarrhoea (4.9%) and pruritus (3.5%). Conclusions: fosamil was well tolerated and did not result in any unexpected safety concerns. The data from the CANVAS trials suggest that ceftaroline fosamil has the expected safety and tolerability profile common to the cephalosporin class. Keywords: cephalosporins, tolerability, QTc intervals Introduction fosamil is a new-generation, parenteral cephalosporin that was developed for the treatment of moderate to severe bacterial infections, including complicated skin and skin structure infections (csssis). fosamil (subsequently referred to as ceftaroline ) is a prodrug that is rapidly converted by plasma phosphatases into active ceftaroline following intravenous (iv) administration. may be considered as both a classic and novel cephalosporin when its spectrum of antibacterial activity is considered. Against common Gramnegative bacteria, such as members of Enterobacteriaceae, non-extended-spectrum b-lactamase-producing Escherichia coli and Klebsiella pneumoniae, ceftaroline exhibits activity similar to third-generation cephalosporins. 1 3 However, bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae is what makes ceftaroline truly noteworthy 4 6 and interesting as a new treatment for csssis. Efficacy is only one part of the risk benefit evaluation. It is equally important to provide therapy that is both safe and well tolerated. The challenge for clinicians is in choosing the best therapeutic option while balancing the risk potential for adverse events (AEs). A number of currently available antimicrobial agents, such as vancomycin, linezolid and daptomycin, # The Author Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org iv67
2 Corrado have been associated with troubling adverse effects, such as vancomycin nephrotoxicity necessitating the need for drug-level monitoring, 7,8 linezolid-associated myelosuppression 9,10 and daptomycin-related elevation of creatine phosphokinase. 11 In contrast, the cephalosporin class has traditionally maintained an excellent safety profile, 12 which is expected to continue as new agents are developed. This report provides an integrated safety summary of the CeftAroliNe Versus VAncomycin in Skin and Skin Structure Infections (CANVAS) 1 and 2 studies (registration numbers NCT and NCT ), which evaluated the efficacy and safety of 600 mg of ceftaroline administered iv every 12 h compared with vancomycin plus aztreonam in adult patients with csssis. Methods The CANVAS trials were designed as parallel, methodologically identical, multicentre, randomized, double-blind, comparative studies to evaluate the safety and efficacy of 600 mg of iv ceftaroline every 12 h versus 1 g of iv vancomycin plus 1 g of iv aztreonam every 12 h in patients with csssis. Details of the study design and integrated results for these two trials were described previously, 13 and efficacy results for the individual CANVAS 1 and CANVAS 2 trials are reported elsewhere in this Supplement. 14,15 This report provides an integrated safety summary of the CANVAS 1 and 2 studies. A total of 1378 patients received any amount of study drug and were included in the safety population for the two CANVAS trials; 692 in the ceftaroline arm and 686 in the vancomycin plus aztreonam arm. All patients who entered into the CANVAS trials met eligibility criteria, and provided informed consent after the risks and requirements of the trial were explained. At study entry (baseline), a history and physical examination, including a detailed evaluation of the infection site(s), were performed. Urine for baseline urinalysis and blood for a complete blood count (CBC), direct and indirect Coombs test, serum chemistry panel, and other laboratory measurements were obtained; 12-lead electrocardiograms were conducted at baseline. Patients were randomized in a blinded fashion to receive ceftaroline or vancomycin plus aztreonam for 5 14 days. All patients were followed for AEs occurring from the start of the initial study drug infusion up to the test-of-cure visit, 1 week following the last dose of study medication; all AEs were followed until resolution or stabilization. All AEs were recorded on case report forms, and assessed for degree of severity and causality by the investigator. Any AEs resulting in death, prolongation of existing hospitalization, a potentially life-threatening event, persistent or significant disability or incapacity, congenital anomaly or birth defect in the offspring of a subject who received study drug, or events that jeopardize the subject sufficiently that medical or surgical intervention may be required to prevent one of the above outcomes was considered a serious adverse event (SAE), regardless of whether or not the AE was judged to be drug related. Such SAEs were recorded if they occurred up to 30 days after the last dose of the study drug; all SAEs were followed until resolution. Urinalysis, CBCs and serum chemistries were repeated at the end of therapy and at the test-of-cure visit or, if felt necessary, at any time during the trial. Results The demographic and baseline characteristics of subjects in the ceftaroline and vancomycin plus aztreonam groups were well balanced in all regards, including race, age, co-morbid conditions and renal function. Thus, the comparative distribution of AEs between the ceftaroline regimen and the vancomycin plus aztreonam regimen was unlikely to be reflective of underlying demographic differences between arms. Treatment-emergent adverse events (TEAEs) were captured regardless of drug relationship and were defined as AEs with onset occurring or severity worsening on or after the first dose of study drug through the test-of-cure visit (for all TEAEs) or late follow-up visit (for SAEs only) (Table 1). The percentage of patients with an SAE (4.3% versus 4.1%) was similar between the ceftaroline and the vancomycin plus aztreonam groups, respectively. Discontinuation rates because of a TEAE were 3.0% for ceftaroline and 4.8% for vancomycin plus aztreonam subjects. Based on these parameters alone, ceftaroline appears as safe and tolerable as vancomycin plus aztreonam. The number of patients with at least one TEAE noted in the CANVAS trials is typical for clinical trials conducted in patients with csssis, as are the SAE and discontinuation rates. Table 1 lists TEAEs resulting in discontinuation of the study drug or withdrawal from the study. Interestingly, hypersensitivity reactions resulted in discontinuation in numerically more vancomycin plus aztreonam subjects than ceftaroline subjects (six versus three), as did rash (four versus two), allergic dermatitis (two versus one) and urticaria (two versus one), respectively. Further, erythema and non-generalized pruritus resulted in discontinuation only for patients on the vancomycin plus aztreonam regimen (eight versus none). Table 2 describes TEAEs seen in either regimen with a frequency of 1% and in which a difference of 0.5% was observed between ceftaroline and vancomycin plus aztreonam. Pruritus, nausea, headache and diarrhoea were the most common of these TEAEs. Only two of the TEAEs demonstrated a difference of.1% between regimens. Diarrhoea occurred in 4.9% of ceftaroline subjects (1.1% more than the vancomycin plus aztreonam regimen) and pruritus occurred in 8.2% of vancomycin plus aztreonam subjects (4.7% more than the ceftaroline regimen). Regarding SAEs, no patterns or signals were demonstrable in either treatment group and virtually all were Table 1. Incidence of TEAEs leading to discontinuation (more than one per regimen) fosamil plus aztreonam (N¼686), n (%) Any TEAE 309 (44.7) 326 (47.5) SAEs 30 (4.3) 28 (4.1) Discontinuation secondary 21 (3.0) 33 (4.8) to TEAE hypersensitivity 3 (0.4) 6 (0.9) generalized pruritus 2 (0.3) 3 (0.4) rash 2 (0.3) 4 (0.6) generalized rash 2 (0.3) 1 (0.1) maculopapular rash 2 (0.3) 0 (0.0) allergic dermatitis 1 (0.1) 2 (0.3) urticaria 1 (0.1) 2 (0.3) erythema 0 (0.0) 5 (0.7) pruritus 0 (0.0) 3 (0.4) iv68
3 Integrated safety summary of CANVAS 1 and 2 JAC Table 2. Comparison of specific TEAEs occurring with a frequency of 1% (with D 0.5% between regimens) fosamil plus aztreonam (N¼686), n (%) Nausea 41 (5.9) 35 (5.1) Headache 36 (5.2) 31 (4.5) Diarrhoea 34 (4.9) 26 (3.8) Pruritus 24 (3.5) 56 (8.2) Rash 22 (3.2) 17 (2.5) Generalized pruritus 15 (2.2) 19 (2.8) Dizziness 14 (2.0) 8 (1.2) Hypokalaemia 10 (1.4) 15 (2.2) Anaemia 9 (1.3) 13 (1.9) Pain 9 (1.3) 4 (0.6) Pyrexia 9 (1.3) 16 (2.3) Chest pain 8 (1.2) 5 (0.7) ALT increase 8 (1.2) 12 (1.7) AST increase 7 (1.0) 13 (1.9) Infusion site erythema 7 (1.0) 2 (0.3) considered unrelated to the study drug; instead, they were related to a co-morbid condition or the underlying skin infection condition. Only one SAE occurred in more than one subject, in the ceftaroline arm, and this was a worsening of the cellulitis. All TEAEs (e.g. headache and nausea) were graded based on severity, as assessed by the investigator, as severe, moderate or mild. If a patient had more than one TEAE of the same term, severity was based on the worst severity rating observed. Generally, the distribution of TEAEs based on severity was comparable between regimens. The majority of patients had no (55.3% versus 52.5%) or mild (23.8% versus 25.7%) TEAEs in the ceftaroline and vancomycin plus aztreonam groups, respectively; 17.1% of ceftaroline-treated patients and 17.3% of vancomycin plus aztreonam-treated patients had moderate TEAEs. Severe TEAEs were reported in 3.8% of ceftaroline and 4.5% of vancomycin plus aztreonam subjects. The lower percentages in each category for ceftaroline were of no clinical relevance. In the renal analyses (Table 3), compared with vancomycin plus aztreonam, fewer ceftaroline subjects had serum creatinine levels rise to.1.5 mg/dl, where that rise also represented a.50% increase over baseline. This was also true for blood urea nitrogen (BUN) and decreases in creatinine clearance of.50%. In this regard, ceftaroline appears to have less of a renal effect than vancomycin plus aztreonam. When TEAEs of the kidney system were reviewed, rather than just chemistries, 1.3% of ceftaroline subjects had at least one such renal TEAE compared with 0.7% of vancomycin plus aztreonam subjects. When these TEAEs, whether related to the study drug or not, were examined further, acute renal failure, the most significant of the renal TEAEs, was more common in vancomycin plus aztreonam recipients (0.4% versus 0.1%). One additional patient in the ceftaroline group had renal failure listed as a TEAE, without defining whether the renal failure was acute or longstanding. Table 4 lists hepatic TEAEs in the CANVAS trials. Among these TEAEs, more vancomycin plus aztreonam-treated subjects had Table 3. Renal abnormalities Serum creatinine.1.5 mg/dl and.50% increase fosamil, plus aztreonam, 6/676 (0.9) 14/664 (2.1) BUN.1.5 ULN and.50% increase 2/676 (0.3) 8/664 (1.2) Creatinine clearance.50% decrease 3/676 (0.4) 7/663 (1.1) At least one renal TEAE 9/692 (1.3) 5/686 (0.7) Renal TEAE occurring in.1 subject per regimen renal impairment 2/692 (0.3) 0/686 (0.0) acute renal failure 1/692 (0.1) 3/686 (0.4) pollakiuria 2/692 (0.3) 1/686 (0.1) dysuria 2/692 (0.3) 2/686 (0.3) Table 4. Incidence of TEAEs indicating potential liver function abnormalities fosamil plus aztreonam (N¼686), n (%) At least one hepatic TEAE 19 (2.7) 29 (4.2) hepatobiliary disorders 2 (0.3) 2 (0.3) toxic hepatitis 1 (0.1) 0 (0.0) hepatomegaly 1 (0.1) 0 (0.0) cytolytic hepatitis 0 (0.0) 1 (0.1) hepatic failure 0 (0.0) 1 (0.1) investigations a 17 (2.5) 27 (3.9) ALT increased 8 (1.2) 12 (1.7) AST increased 7 (1.0) 13 (1.9) transaminases increased 2 (0.3) 0 (0.0) hepatic enzyme increased 1 (0.1) 6 (0.9) liver function tests abnormal 1 (0.1) 4 (0.6) a Incidence of subjects with at least one TEAE reflecting elevated liver enzymes. at least one TEAE referable to the hepatic system. Subjects who had a clinical TEAE, such as hepatic failure, plus a TEAE of abnormal liver function test are also represented in Table 4 under investigations (any TEAEs reflecting elevated liver enzymes); thus, they are described both as a clinical TEAE and investigation. This accounts for the difference in the percentage of subjects with at least one TEAE versus the summation of TEAEs described in Table 4. Table 5 looks specifically at liver function tests in a different way. Minor elevations in liver tests are difficult to evaluate and often of little meaning. However, by looking at significant increases or patterns of various tests together, a more meaningful evaluation and prediction of hepatocellular toxicity can be made. Table 5 describes increases in multiples of the upper limit of normal (ULN) for various tests. The vancomycin plus aztreonam regimen resulted more often in.3-fold iv69
4 Corrado Table 5. Liver function abnormalities or.5-fold increases above the ULN for both aspartate aminotransferase (AST) and, more significantly, alanine aminotransferase (ALT), because this measure is more specific for the liver. The most sensitive analysis of the potential to evoke hepatocellular damage is an analysis of subjects who have an increase in ALT or AST.3-fold above the ULN, less than a 2-fold increase in alkaline phosphatase plus a.2-fold increase in bilirubin above the ULN, in the same patient. This was not noted in any patient. Certain TEAEs of interest in the CANVAS trials were evaluated because of their known association with b-lactams or with other antibacterial classes. Diarrhoea was the most common of these TEAEs in both treatment groups, with 4.9% in the ceftaroline group compared with 3.8% in the vancomycin plus aztreonam group. During the CANVAS trials, three subjects had Clostridium difficile reported (two on ceftaroline and one on vancomycin plus aztreonam). No patients in either group experienced prolongation of the QT interval. Although a small percentage of patients receiving cephalosporins are known to test positive for direct Coombs, there is no clear association 12,20 23 with this finding and the risk of haemolytic anaemia. In the CANVAS trials, 11.6% of ceftaroline patients and 4.3% of vancomycin plus aztreonam patients tested positive in the direct Coombs test. Both treatment regimens, however, had,2% of the treated patients identified as having a TEAE suggestive of anaemia, none of which was haemolytic anaemia. Finally, only one patient had a seizure disorder, a ceftaroline patient. These data suggest that ceftaroline is safe and well tolerated, with a safety profile that is consistent with the cephalosporin class. Discussion fosamil, plus aztreonam, AST.3 ULN 6/510 (1.2) 13/488 (2.7) AST.5 ULN 1/510 (0.2) 5/488 (1.0) ALT.3 ULN 4/542 (0.7) 12/527 (2.3) ALT.5 ULN 3/542 (0.6) 5/527 (0.9) Total bilirubin.1.5 ULN 1/628 (0.2) 1/619 (0.2) ALT or AST.3 ULN, ALP,2 ULN 0/655 (0.0) 0/649 (0.0) and total bilirubin.1.5 ULN ALT or AST.3 ULN, ALP,2 ULN and total bilirubin.2 ULN 0/656 (0.0) 0/649 (0.0) ALP, alkaline phosphatase. On 8 June 1908, Paul Erhlich delivered a paper in which he described the objectives of modern chemotherapy of infectious diseases. 24 Ehrlich described his search for structural modifications in arsenicals that were less toxic for the host and yet effective in eradicating an infection. From that time forward pharmaceutical scientists have examined this balancing act, looking for new drugs or novel modifications to older classes of drugs to treat resistant infections while maintaining the lowest toxic potential for patients. The discovery of penicillin, the first b-lactam, by Alexander Fleming, 25 and the subsequent identification of the structurally related cephalosporins 26 seemed to represent the discovery of ideal drugs. Although cefaloridine, unlike cefalotin, could be comfortably given intramuscularly, it was found to have nephrotoxic potential. 22 Subsequently, numerous cephalosporins have been developed, each with marginal or significant expansion in the spectrum of activity and safety profile. Although the occasional cephalosporin exhibits a unique toxicity (e.g. moxalactam-associated bleeding), overall, the cephalosporins as a class have maintained an excellent record of safety and tolerability, 12 and are among the most frequently prescribed classes of antimicrobials. In this analysis of the CANVAS studies, no new safety concerns for ceftaroline were noted in.1300 patients evaluated. Both ceftaroline and vancomycin plus aztreonam were well tolerated in the integrated safety analysis, and the incidence of TEAEs was similar between groups. The TEAEs shown in Table 2 are generally those that are common in any study population, and have previously been described in association with cephalosporin and/or vancomycin use. 12 The most commonly reported TEAEs in patients treated with ceftaroline included nausea, headache, diarrhoea and pruritus. It is generally accepted that 5% of the population develop allergic reactions to cephalosporins, 22 and the results from the CANVAS trials suggest a similar rate for ceftaroline. Notably, hypersensitivity reactions resulted in more discontinuations in vancomycin plus aztreonam patients than in ceftaroline subjects. In this study, the majority of patients (.75%) had either no or mild TEAEs and the distribution of TEAEs based on severity was comparable between groups. There was no indication of potential to evoke renal or hepatocellular damage. The fact that no prolongation in the QT interval was seen is consistent with previous data that showed no clinically meaningful QT interval prolongation with ceftaroline 27 and is in keeping with the belief that this is not an event associated with b-lactam antibiotics. The data from the CANVAS trials, which should be confirmed in other clinical studies, suggest that ceftaroline, as a novel cephalosporin, has the traditional safety and tolerability profile that is expected and prized of this class of agents. At this time there appear to be no unusual risks associated with ceftaroline compared with other cephalosporins. It is only the passage of time and the cumulative experience with ceftaroline use that will fully elucidate the complete safety profile of this agent. Based on the safety and tolerability profile of ceftaroline, as well as the efficacy (described separately in this Supplement) demonstrated in the CANVAS trials, it would appear, and is likely to be the case, that ceftaroline fulfils the Ehrlich directive for modern chemotherapy of infectious diseases of a safe and effective antimicrobial agent. offers clinicians a safe and simple monotherapy option, without the need for extensive laboratory monitoring, for the management of csssis when empirical coverage for Gram-positive and Gram-negative pathogens is warranted. Funding Funding for editorial assistance was provided by Forest Laboratories, Inc. iv70
5 Integrated safety summary of CANVAS 1 and 2 JAC Transparency declarations This article was developed from a scientific panel of CANVAS investigators and experts in skin and skin structure infections, held on August 2009 in New York, NY, USA. This article is part of a Supplement sponsored by Forest Laboratories, Inc. M. L. C. has received no funding or pecuniary compensation of any kind other than an honorarium for participation time. Grace Johnson and Monica Dodge of Scientific Therapeutics Information, Inc. (Springfield, NJ, USA) provided editorial assistance on this manuscript. References 1 Mushtaq S, Warner M, Ge Y et al. In vitro activity of ceftaroline (PPI- 0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60: Talbot GH, Thye D, Das A et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51: Zhanel GG, Sniezek G, Schweizer F et al. : a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus. Drugs 2009; 69: Jacqueline C, Caillon J, Le Mabecque V et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007; 51: Parish D, Scheinfeld N. fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs 2008; 9: Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52: Lodise TP, Patel N, Lomaestro BM et al. Relationship between initial vancomycin concentration time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: Rybak MJ, Lomaestro BM, Rotscahfer JC et al. therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: Attassi K, Hershberger E, Alam R et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34: Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009; 59 Suppl 1: S Bhavnani SM, Rubino CM, Ambrose PG et al. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50: Andes DR, Craig WA. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett s Principles and Practice of Infectious Diseases. 6th edn. Philadelphia: Elsevier Inc., 2005; Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51: Corey GR, Wilcox MH, Talbot GH et al. on behalf of the CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv Wilcox MH, Corey GR, Talbot GH et al. on behalf of the CANVAS 2 investigators. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv Breedt J, Teras J, Gardovskis J et al. for the Tigecycline 305 csssi Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin aztreonam. Antimicrob Agents Chemother 2005; 49: Noel GJ, Bush K, Bagchi P et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46: Stryjewski ME, Graham DR, Wilson SE et al. on behalf of the Assessment of Telavancin in Complicated Skin, Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46: Ellis-Grosse EJ, Babinchak T, Dartois N et al. for the Tigecycline 300 and 305 csssi Study Groups. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin aztreonam. Clin Infect Dis 2005; 41 Suppl 5: S Gustaferro CA, Steckelberg JM. Cephalosporin antimicrobial agents and related compounds. Mayo Clin Proc 1991; 66: Roy RB, Doris L, Beanlands DS. Positive direct Coombs test without hemolytic anemia, attributed to penicillin therapy. Can Med Assoc J 1968; 99: Weinstein L. Antibiotics. In: Goodman LS, Gilman A, eds. Goodman and Gilman s the Pharmacological Basis of Therapeutics: A Textbook of Pharmacology, Toxicology, and Therapeutics for Physicians and Medical Students. 4th edn. New York: Macmillan, 1970; Weinstein L, Kaplan K. The cephalosporins: microbiological, chemical, and pharmacological properties and use in chemotherapy of infection. Ann Intern Med 1970; 72: Erhlich P. Über moderne Chemotherapie. In: Erhlich P, ed. Beiträge zur Experimentellen Pathologie und Chemotherapie. Leipzig: Akademische Verlagsgesellschaft, 1909; Fleming A. On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929; 10: Brotzu G. Richerche su di un nuovo antibiotico. Lav Ist Ig Cagliari, Cited by Abraham EP. The cephalosporins. Pharmac Rev 1962; 14: Data on file (Forest Laboratories, Inc.). A randomized, double-blind, placebo-controlled, crossover study to evaluate the safety, pharmacokinetics, and effect on the electrocardiogram of a supratherapeutic dose of ceftaroline in healthy subjects (Study P903-05) iv71
ESCMID Online Lecture Library. by author
Hospital Universitario Virgen Macarena, Seville New drugs against MRSA and VRE L. Eduardo López Cortés Seville, 8th July Tedizolid Oxazolidinone Ceftaroline // Ceftobiprole 5 th gen cephalosporin Overview
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
More informationOpen Forum Infectious Diseases MAJOR ARTICLE
Open Forum Infectious Diseases MAJOR ARTICLE Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting:
More informationReceived 30 March 2005; returned 16 June 2005; revised 8 September 2005; accepted 12 September 2005
Journal of Antimicrobial Chemotherapy (2005) 56, 1047 1052 doi:10.1093/jac/dki362 Advance Access publication 20 October 2005 Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity,
More informationConsideration of some other specific indications: Bacteremia
European Medicines Agency Workshop on Antibacterials, London 7-8 February 2011 Consideration of some other specific indications: Bacteremia Harald Seifert Institut für Medizinische Mikrobiologie, Immunologie
More informationOutpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry
doi: 10.1111/j.1742-1241.2008.01824.x ORIGINAL PAPER Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry W. J. Martone, K. C. Lindfield, D. E. Katz OnlineOpen: This
More informationPART VI. SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for ZINFORO
PART VI. SUMMARY OF THE RISK MANAGEMENT PLAN Summary of risk management plan for ZINFORO This is a summary of the risk management plan (RMP) for ZINFORO. The RMP details important risks of ZINFORO, how
More informationSafety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
Drug Saf (2016) 39:147 157 DOI 10.1007/s40264-015-0374-9 ORIGINAL RESEARCH ARTICLE Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative
More informationEDUCATIONAL COMMENTARY VANCOMYCIN MONITORING
EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationMesporin TM. Ceftriaxone sodium. Rapid onset, sustained action, for a broad spectrum of infections
Ceftriaxone sodium Rapid onset, sustained action, for a broad spectrum of infections 1, 2, 3 Antibiotic with a broad spectrum of activity Broad spectrum of activity against gram-positive* and gram-negative
More informationVancomycin Drug Class 1
Drug Class 1 Antibiotic glycopeptide Spectrum 1 Cross Sensitivities / Allergies 1 Refer to product monograph for complete spectrum Gram positive pathogens (e.g., S. aureus, Enterococcus, S. viridans, methicillinresistant
More information400 mg IV (over 5 to 60 minutes) every 12 hours. > 30 to mg IV (over 5 to 60 minutes ) every 12 hours. 15 to 30
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEFLARO safely and effectively. See full prescribing information for TEFLARO. TEFLARO (ceftaroline
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationPharmacokinetics of daptomycin in a patient with severe renal failure not under dialysis
AAC Accepts, published online ahead of print on 1 April 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00230-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Pharmacokinetics
More informationEfficacy of Ceftaroline Fosamil against Escherichia coli and Klebsiella pneumoniae Strains in a rabbit meningitis model.
AAC Accepts, published online ahead of print on 3 September 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.00285-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 1 2 Efficacy
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME Zinforo 600 mg powder for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains ceftaroline fosamil acetic acid solvate monohydrate equivalent
More informationEvaluation of Vancomycin Continuous Infusion in Trauma Patients
OBJECTIVES Evaluation of Vancomycin Continuous Infusion in Trauma Patients Brittany D. Bissell, Pharm.D. PGY-2 Critical Care Pharmacy Resident Jackson Memorial Hospital Miami, Florida Evaluate the potential
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY Volume 23 Number 6 June 2017 C Ceftaroline: An Alternative Broad Spectrum Antibiotic for Pediatric Infections Marcia L. Buck, PharmD, FCCP, FPPAG, BCPPS eftaroline was approved
More informationCubicin A Guide to Dosing
Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections
More informationActivity of Ceftolozane/Tazobactam Against a Broad Spectrum of Recent Clinical Anaerobic Isolates
AAC Accepts, published online ahead of print on 25 November 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.02253-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. Activity
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aztreonam Pharmaceutical form(s)/strength: 500 mg, 1 g and 2 g powder for solution for injection and infusion NB! 75mg aztreonam for nebulisation to treat infections
More informationInitial U.S. Approval: 2010
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TEFLARO safely and effectively. See full prescribing information for TEFLARO. TEFLARO (ceftaroline
More informationOptions for Complicated Skin and Skin Structure Infections. Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ.
Options for Complicated Skin and Skin Structure Infections Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator for,
More informationDurvalumab (previously known as MEDI 4736) Maintenance (Arm A3) PLATFORM study
Durvalumab (previously known as MEDI 4736) Maintenance (Arm A3) PLATFORM study PLAnning Treatment For Oesophago-gastric cancer: a Randomised Maintenance therapy trial. ***See Protocol for further details***
More informationVANLID Capsules (Vancomycin hydrochloride)
Published on: 22 Sep 2014 VANLID Capsules (Vancomycin hydrochloride) Composition VANLID Capsules Each capsule contains: Vancomycin Hydrochloride IP equivalent to Vancomycin.. 250 mg Approved colours used
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationSBUH Aminoglycoside Dosing Protocol
Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT
More informationDepartment of Pharmacy Services, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA; 2
Pathogens 2015, 4, 599-605; doi:10.3390/pathogens4030599 Article OPEN ACCESS pathogens ISSN 2076-0817 www.mdpi.com/journal/pathogens Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for
More informationOther β-lactam. A. Carbapenems:
A. Carbapenems: Other β-lactam Carbapenems are synthetic β-lactam antibiotics Differ in structure from the penicillins in that the sulfur atom of the thiazolidine ring. Imipenem, meropenem, doripenem,
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationPACKAGE INSERT USP ANTIBIOTIC
Pr AMPICILLIN for Injection USP ANTIBIOTIC ACTIONS AND CLINICAL PHARMACOLOGY Ampicillin has a broad spectrum of bactericidal activity against many gram-positive and gramnegative aerobic and anaerobic bacteria.
More informationWebposting Clinical Trial Results Synopsis
Study Summary This summary information is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This summary information is not intended to replace
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationDecember 3, 2015 Severe Sepsis and Septic Shock Antibiotic Guide
Severe Sepsis and Septic Shock Antibiotic Guide Surviving Sepsis: The choice of empirical antimicrobial therapy depends on complex issues related to the patient s history, including drug intolerances,
More informationMipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3
(ISIS 301012) Page 2 of 1979 2 SYNOPSIS ISIS 301012-CS3 synopsis Page 1 Title of Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics,
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationUse of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience
Johnson et al. BMC Infectious Diseases (2019) 19:183 https://doi.org/10.1186/s12879-019-3791-z RESEARCH ARTICLE Open Access Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience Leonard
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationRochester Patient Safety C. difficile Prevention Collaborative: Long Term Care Antimicrobial Stewardship (funded by NYSDOH)
Rochester Patient Safety C. difficile Prevention Collaborative: Long Term Care Antimicrobial Stewardship (funded by NYSDOH) Clinical Practice Guideline* for the Diagnosis and Management of Acute Bacterial
More informationClinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)
VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin
More informationWARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS
DECLESAU (dergrafloxacin) tablets, for oral use DECLESAU (dergrafloxacin) injection, solution for intravenous use WARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including
More informationStudy No.: ADF Title: Phase III study of adefovir dipivoxil (ADV) tablets in patients with compensated chronic hepatitis B -comparative study
Study No.: ADF105220 Title: Phase III study of adefovir dipivoxil () tablets in patients with compensated chronic hepatitis B -comparative study against lamivudine ()- Rationale: This study wass a confirmatory
More informationPlazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study Daniel J. Cloutier 1, Loren G. Miller 2, Allison S. Komirenko 1,
More informationAXITAB-CV TAB. COMPOSITION :
AXITAB-CV TAB. COMPOSITION : Each film coated tablet contains: Cefuroxime Axetil I.P. Eq. to Anhydrous 500mg. Potassium Clavulanate Diluted I.P. Eq. to Clavulanic Acid 125mg DESCRIPTION : Cefuroxime Axetil
More informationTrust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More informationAminoglycosides John A. Bosso, Pharm.D.
AMINOGLYCOSIDES Therapeutics/PHRMP-73 Aminoglycoside Mechanism of Action Aminoglycosides bind to 30s ribosomal subunit resulting in mistranslation of mrna thus disrupting protein synthesis. They are rapidly
More informationCisplatin / Paclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual
More informationIndividual Study Table Referring to Part of Dossier: Use Only) Name of Study Drug:
2.0 Synopsis AbbVie Inc. Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Adalimumab (Humira ) Page: Name of Active Ingredient: Adalimumab
More informationZINEX. Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg
ZINEX Composition Each tablet contains Cefuroxime (as axetil) 250 or 500 mg Tablets Action Cefuroxime axetil owes its bactericidal activity to the parent compound cefuroxime. Cefuroxime is a well-characterized
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods
Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services
More informationNew Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationAmoxitid 125 Suspension Each teaspoonful (5 ml) contains Amoxicillin (as trihydrate) 125 mg.
AMOXITID Composition Amoxitid 250 Capsules Each capsule contains Amoxicillin (as trihydrate) 250 mg. Capsules & Suspension Amoxitid 500 Capsules Each capsule contains Amoxicillin (as trihydrate) 500 mg.
More informationDocetaxel + Nintedanib
Docetaxel + Nintedanib Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Second
More informationCeftaroline fosamil, as ceftaroline fosamil monoacetate monohydrate.
PRODUCT INFORMATION ZINFORO ceftaroline fosamil NAME OF THE MEDICINE Ceftaroline fosamil, as ceftaroline fosamil monoacetate monohydrate. The chemical name of ceftaroline fosamil monoacetate monohydrate
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Pneumococcal infection is a major cause of morbidity mortality worldwide. In 2005, WHO estimated that 1.6 million deaths were
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More information(telavancin) Healthcare Professional s Guide. Version 2, 4 November 2014
VIBATIV (telavancin) Healthcare Professional s Guide Version 2, 4 November 2014 1 Table of Contents Introduction... 3 About Vibativ / Therapeutic indications... 3 Antimicrobial spectrum of activity for
More informationD DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2
Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following
More informationlife-threatening infections
Vancomycin Vancomycin has become increasingly important in the treatment of life-threatening infections. MRSA infections. Methicillin-resistant Staphylococcus epidermidis (MRSE) infections Enterococcal
More informationAnnex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications
Annex I: Proposed Core Safety Profile (CSP) 4.3 Contraindications Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1. Patients with known hypersensitivity to cephalosporin
More informationSynopsis. Adalimumab M Clinical Study Report R&D/09/060. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Volume: (For National Authority Use Only) Name of Active Ingredient: Page: Title of Study: A Multi-Center,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClarithromycin versus penicillin in the treatment of streptococcal pharyngitis
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. A, 67-74 Clarithromycin versus penicillin in the treatment of streptococcal pharyngitis Joseph H. Levenstein* South Africa Academy of Family Practice,
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationORIGINAL ARTICLE DOI: (e) ISSN Online: (p) ISSN Print: Anand Kumar Singh 1, Poonam Verma 2. Sciences, Dehradun
ORIGINAL ARTICLE CLINICAL ASSESSMENT OF NEPHROTOXICITY ASSOCIATED WITH VANCOMYCIN TROUGH CONCENTRATIONS DURING TREATMENT OF DEEP-SEATED INFECTIONS: A RETROSPECTIVE ANALYSIS Anand Kumar Singh 1, Poonam
More informationEffect of piperacillin/tazobactam restriction on usage and rates of acute renal failure
Journal of Medical Microbiology (2016), 65, 195 199 DOI 10.1099/jmm.0.000211 Effect of piperacillin/tazobactam restriction on usage and rates of acute renal failure Michael A. Lorenz, 1,2 Ryan P. Moenster
More informationEvidence for the use of new and old agents for MRSA infection. Dr Charis Marwick Ninewells Hospital & Medical School Dundee
Evidence for the use of new and old agents for MRSA infection Dr Charis Marwick Ninewells Hospital & Medical School Dundee 32 year old man Admitted unwell for few days Cough, fever, short of breath, pleuritic
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nicef Capsules 250mg / Cefradine Capsules 250mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Ingredient Cefradine Ph Eur 3 PHARMACEUTICAL
More informationComparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia
Comparison of Meropenem with Ceftazidime as Monotherapy of Cancer Patients with Chemotherapy induced Febrile Neutropenia I. Malik ( National Cancer lnsititute, Karachi ) Shaharyar (, Department of Radiotherapy
More informationInfectious Disease in the Critically Ill Patient
Infectious Disease in the Critically Ill Patient Heather L. Evans, MD MS FACS Director of Surgical Infectious Disease Harborview Medical Center Asst. Professor UW Department of Surgery New Antibiotics:
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationSynopsis Style Clinical Study Report SAR ACT sarilumab Version number : 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Ingredient Cefradine Ph Eur 3 PHARMACEUTICAL FORM Capsules. 4 CLINICAL PARTICULARS Per
More informationClinical Study Synopsis
Clinical Study Synopsis This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before
More informationTRANSPARENCY COMMITTEE OPINION. 15 October Date of Marketing Authorisation (national procedure): 16 April 1997, variation of 18 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 October 2008 MERONEM 1 g, powder for solution for IV Injection Box of 10 vials (CIP: 387 830-6) Applicant: ASTRAZENECA
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationOmnix Tablets / DT / Dry Syrup (Cefixime)
Published on: 22 Sep 2014 Omnix Tablets / DT / Dry Syrup (Cefixime) Composition OMNIX-50 DT Each uncoated dispersible tablet contains: Cefixime, IP, as a trihydrate equivalent to Anhydrous Cefixime...
More informationPharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml SI/H/PSUR/0002/002 Date of FAR:
0BCore Safety Profile Active substance: Ceftibuten Pharmaceutical form(s)/strength: Capsules, 200mg, 400mg, Oral suspensions, 90mg/5ml, 180mg/5ml, 36 mg/ml P-RMS: SI/H/PSUR/0002/002 Date of FAR: 14.02.2013
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationPaclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly
More informationNew Medicines Committee Briefing. July Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection
New Medicines Committee Briefing July 2014 Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection (unlicensed indication) Fosfomycin trometamol to be reviewed for use within:
More informationSkin and soft tissue (SSTI) sepsis (surgery, antimicrobial therapy and more)
Skin and soft tissue (SSTI) sepsis (surgery, antimicrobial therapy and more) Christian Eckmann Antibiotic Stewardship Expert ECDC Chief of Staff Department of General, Visceral and Thoracic Surgery Klinikum
More informationCubicin (Daptomycin) Priv.Doz. Dr. med. Markus Rothenburger
Cubicin (Daptomycin) Priv.Doz. Dr. med. Markus Rothenburger Cubicin (Daptomycin): A new generation of antibiotics First-in-class cyclic natural lipopeptide Activity against major gram positive pathogens
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationKEFZOL (cephazolin, as cephazolin sodium)
PRODUCT INFORMATION KEFZOL (cephazolin, as cephazolin sodium) DESCRIPTION Kefzol (cephazolin sodium) is a semisynthetic cephalosporin for parenteral administration. It is the sodium salt of 3-[[(5-methyl-1,3,4-thiadiazol-2-yl)-thio]
More informationVISA infections. Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis
VISA infections Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis jeanralph.zahar@aphp.fr H VISA and VISA infections Jean Ralph Zahar Infection Control Unit GH Paris Seine Saint Denis
More informationClinical Comparison of Cefotaxime with Gentamicin plus Clindamycin in the Treatment of Peritonitis and Other Soft-Tissue Infections
REVIEWS OF INFECTIOUS DISEASES. VOL. 4, SUPPLEMENT. SEPTEMBER-OCTOBER 982 982 by The University of Chicago. All rights reserved. 062-0886/82/0405-022$02.00 Clinical Comparison of with Gentamicin plus Clindamycin
More informationPFIZER INC. Study Center(s): A total of 6 centers took part in the study, including 2 in France and 4 in the United States.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationVANCOMYCIN DOSING AND MONITORING GUIDELINES
VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal
More informationShirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate
Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate Professor of Pharmacy & Associate Member of Medicine, UBC
More informationComparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects
Comparison of Omadacycline and Tigecycline Pharmacodynamics in the Plasma, Epithelial Lining Fluid, and Alveolar Macrophages in Healthy Subjects Karolyn S. Horn, Mark H. Gotfried, Judith N. Steenbergen,
More information